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Introduction
Pediatric low- grade gliomas (PLGGs) exhibit molecular 
genetic alterations different from that of the adult popula-
tion. Clinically, PLGGs are generally characterized by slow 
growth rates, a low risk of malignant transformation, and 
excellent long- term survival rates [1–5]. Surgery is regarded 
the cornerstone of treatment: For those harboring 
completely resectable tumors, long- term progression- free 
survival (PFS) can be expected after surgery alone. In 
case of incompletely resectable or unresectable tumors, 
however, PFS becomes significantly shorter leading to the 
initiation of adjuvant treatment concepts including chemo-
therapy or radiotherapy relatively early during the history 
of the disease [6–8]. Given the non- negligible risk of 
short- and long- term side effects of adjuvant treatment 
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Abstract
To analyze efficacy, functional outcome, and treatment toxicity of low- dose rate 
I- 125 brachytherapy (SBT) alone or in combination with best safe resection (in 
case of larger tumor volumes) as first- line treatment for pediatric low- grade 
gliomas (PLGGs) not suitable for complete resection. Consecutively treated 
(2000–2014) complex located circumscribed WHO grade I/II PLGGs were in-
cluded. For small tumors (≤4 cm in diameter) SBT alone was performed; for 
larger tumors best safe resection and subsequent SBT was chosen. Temporary 
Iodine- 125 seeds were used (median reference dose: 54 Gy). Treatment response 
was estimated with the modified MacDonald criteria. Analysis of functional 
outcome included ophthalmological, endocrinological and neurological evalua-
tion. Survival was analyzed with the Kaplan–Meier method. Prognostic factors 
were obtained from proportional hazards models. Toxicity was categorized ac-
cording to the Common Terminology Criteria for Adverse Events. Fifty- eight 
patients were included treated either with SBT alone (n = 39) or with SBT plus 
microsurgery (n = 19). Five- year progression- free survival was 87%. Two patients 
had died due to tumor progression. Among survivors, improvement/stabiliza-
tion/deterioration of functional deficits was seen in 20/14/5 patients, respectively. 
Complete/partial response had beneficial impact on functional scores (P = 0.02). 
The 5- year estimated risk to receive adjuvant radiotherapy/chemotherapy was 
5.2%. The overall early (delayed) toxicity rate was 8.6% (10.3%), respectively. 
No permanent morbidity occurred. In complex located PLGGs, early SBT alone 
or combined with best safe resection preserves/improves functional scores and 
results in tumor control rates usually achieved with complete resection. Long- 
term analysis is necessary for confirmation of these results.
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concepts currently in use [1, 6, 9–12], ongoing interest 
exists to further expand the platform of localized treat-
ment concepts for PLGG patients. A previously published 
pilot study has suggested that low- dose rate stereotactic 
Iodine- 125 brachytherapy (SBT) allowing precise applica-
tion of ablative tumor doses with maximum sparing of 
surrounding normal tissues might contribute to the spec-
trum of localized treatment concepts for complex located 
PLGGs; in that study SBT was used either alone in case 
of small- sized unresectable tumors or coupled with best 
safe resection (in case of larger tumor volumes) and has 
turned out to be feasible and safe [13]. A small sample 
size and short follow- up periods, however, were limita-
tions of this study. For further clarification this study 
was conducted. Stereotactic Iodine- 125 brachytherapy 
(SBT) alone or in combination with surgery was stringently 
used as front- line therapy. Stereotactic Iodine- 125 brachy-
therapy (SBT) was preferred for complex located small- 
sized tumors, whereas best safe resection plus subsequent 
SBT of the residual tumor was used for larger (diameter 
>4 cm) complex located PLGGs. Besides traditional end-
points such as PFS, we focused on functional outcome 
and side effects of the therapy. It was hypothesized that 
early SBT – either alone or in combination with micro-
surgery – would be safe and enhance treatment efficacy 
for those who would otherwise had received biopsy only 
or partial tumor resection.
Methods
Patients
Histologically proven circumscribed and complex located 
WHO grade I or II PLGGs (<18 years of age) not suit-
able for gross total resection were considered eligible for 
this study. Patients were consecutively enrolled between 
April 2000 and April 2014. Tumor classification was per-
formed according to the WHO criteria [14]. Patients data 
of the pilot study were updated and also included [13]. 
Deep seated nonlobar located supratentorial tumors 
(including those infiltrating the insula of Reil), lobar located 
tumors involving functionally relevant areas (such as the 
primary motoric cortex or language- related areas), and 
infratentorial tumors involving the brainstem or the cer-
ebellar peduncle were classified as complex located tumors. 
Circumscribed tumors were those exhibiting nearly identi-
cal tumor volumes on both T1- and T2- magnetic reso-
nance imaging (MRI) sequences. Before study inclusion, 
all tumors had to be classified as either incompletely 
resectable or unresectable. “Resectability” had been assessed 
by two experienced neurosurgeons (J. C. T, A. P) in the 
context of an interdisciplinary tumorboard. Tailored treat-
ment concepts were applied prospectively according to 
the study protocol of the pilot study: [13] Stereotactic 
Iodine- 125 brachytherapy (SBT) alone was indicated in 
circumscribed tumors with a maximum diameter of 4 cm. 
Best safe resection was initiated for larger tumors with a 
diameter of more than 4 cm; SBT of the residual tumor 
was initiated 10–12 weeks after microsurgery (Fig. 1). All 
patients were required to have measurable disease on MRI. 
All patients undergoing SBT only received stereotactic 
biopsy for histological and molecular- genetic characteriza-
tion as described previously [15, 16]. Stereotactic Iodine- 125 
brachytherapy (SBT) was performed immediately after 
biopsy if the intraoperative evaluation indicated grade I/
II histology. In uncertain cases, the result of paraffin 
embedded tissue examination was awaited and SBT was 
done 5–7 days later. A small subset of patients (n = 5) 
had received chemotherapy before study inclusion which 
was not considered an exclusion criterion. No patients 
had undergone initial radiotherapy. Informed consent was 
obtained from the parents or legal guardians and whenever 
possible from the patients themselves. The study protocol 
was reviewed and approved by the institutional review 
board (UE Nr. 131–14).
Best safe resection
Neuronavigation, intraoperative ultrasound, and intraop-
erative neurophysiological monitoring/mapping techniques 
were used as described previously [13, 17–19]. The antici-
pated extent of resection was preoperatively determined 
Figure 1. Study design.
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by both, two experienced neurosurgeons (J. C. T, A. P) 
and the stereotactic neurosurgeon (F. W. K.). It was aimed 
to define a threshold volume suitable for subsequent SBT.
SBT protocol
Stereotactic Iodine- 125 brachytherapy (SBT) was done as 
described previously [13, 20, 21]. Briefly, 3D- treatment 
planning was performed with the @target software pro-
gram (Brainlab, Feldkirchen, Germany) on the basis of 
colocalized CT- and MRI- data. Low- activity temporary 
Iodine- 125 seeds (<20 mCi) were exclusively used. Tumors 
were treated with a reference dose (calculated to the outer 
rim of the tumor) of 54 Gray (Gy); the dose rate was 
low (≤12 cGy/h). Treatment parameters were in line with 
those of numerous prospective and retrospective reports 
[21–23]. In case of larger tumor volumes the reference 
dose was adjusted accordingly (50 Gy or even 45 Gy). 
Conformal irradiation of complex located tumors was 
achieved by implantation of multiple radioactive sources 
(e.g., 3–4 seed catheters). Representative examples are 
given in Figure 2–4.
Molecular genetic profiling
From 2006 onwards molecular- genetic analyses were strin-
gently performed as described previously. The O6- 
methylguanine- DNA methyltransferase (MGMT) promoter 
methylation status was assessed by methylation- specific 
polymerase chain reaction (PCR) and bisulfite sequencing; 
[24] for the determination of loss of heterozygosity (LOH) 
on 1p/19q status microsatellite analysis was used; [25] 
both, isocitrate dehydrogenases (IDH1/2) and BRAFV600E 
mutational status were assessed by pyrosequencing [26, 
27]. For the determination of the BRAF-KIAA1549 fusion 
transcripts PCR was used [28].
Figure 2. Selected treatment example indicating a child with a WHO grade I astrocytoma of the brainstem with exophytic growth undergoing 
combined treatment; (A) before treatment, (B) after best safe resection, (C) Iodine- 125 stereotactic brachytherapy (SBT) irradiation planning (three 
seeds), (D) 18 months post SBT showing partial response (PR).
A B
C D
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Patient evaluation
Clinical and neuroradiological examination were performed 
preoperatively, within 3 days after tumor resection, 
3 months after SBT and then in 6 months intervals. 
Magnetic resonance imaging (MRI) was performed on 1.5T 
or 3.0T scanners (Magnetom Symphony, Siemens; or Signa 
HDxt, GE Healthcare, WI, USA). The standardized protocol 
comprised an axial T2- weighted sequence (slice thickness: 
2 mm) and 3D T1- weighted sequences (slice thickness: 
1 mm) before and after administration of gadopentetate 
dimeglumine (0.1 mmol per kilogram of body weight 
[Magnevist, Schering] Berlin, Germany). Preoperative 
tumor volume was defined by outlining the contour of 
the lesion on each slice of the respective MRI sequence. 
Volume calculation was done using the @target software 
program. Postoperative follow- up MR investigations some-
times slightly differed from the preoperative protocol in 
terms of slice thickness and were partially performed in 
an outpatient setting. Treatment response was assessed 
according to the modified MacDonald criteria for low- 
grade gliomas [29]. This was done at the time of last 
follow- up for those without tumor progression. In those 
suffering from tumor progression over time the MRI before 
progression was used for assessment of the best treatment 
response. Tumor size after SBT was determined by the 
product of the two largest perpendicular diameters of the 
hyperintense T2 lesion in nonenhancing tumors. In enhanc-
ing tumors response criteria considered both the size of 
the hyperintense T2 lesion and any changes of the enhanced 
T1- weighted images. Pseudoprogression was assumed when 
contrast enhanced areas after SBT transiently increased 
and resolved thereafter. Treatment toxicity was classified 
according to the Common Terminology Criteria for Adverse 
Events (CTCAE), Version 4.0 NIH, 2010. Acute toxicities 
were identified as events that arose within 90 days of the 
Figure 3. Selected treatment example indicating a child exhibiting a circumscribed WHO grade II glioma of the brainstem undergoing Iodine- 125 
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start of SBT and late toxicities as events that occurred 
thereafter. All MRI scans were independently reviewed by 
two experienced neuroradiologists (L. E, G. F). In case 
of discordant findings a conference for reevaluation was 
initiated to achieve a consensus concerning the final radio-
logical evaluation. In case of suspected tumor progression 
stereotactic biopsy or open surgery was performed to verify 
tumor progression/malignant transformation.
For performance analyses before treatment and at the 
time of last follow- up the Lansky score [30] was assessed. 
Evaluation of functional scores before treatment and at 
follow- up investigations included motor, visual, endocrine 
function and seizure activity; it was independently per-
formed by the attending pediatric physicians, ophthalmolo-
gists, and endocrinologists. The current analysis referred 
to functional parameters at the time of last follow- up 
for those exhibiting no tumor progression. For those 
exhibiting tumor progression last findings before tumor 
progression were used. Deficits in motor function were 
distributed into mild (muscle strength grade 4–5 accord-
ing to the British Medical Research Council grading system, 
mild ataxia) and severe (muscle strength ≤4, severe ataxia). 
Functional outcome was classified as improved (complete 
disappearance of a mild motor deficit, improvement from 
a severe to a mild deficit), deteriorated (worsening from 
a mild to a severe motor deficit, appearance of a new 
motor deficit) and unchanged (stabilized motor deficit). 
Ophthalmological tests included visual acuity measure-
ments, perimetry of the visual field and oculomotor func-
tion. Evaluation was performed in children exhibiting 
tumors in the hypothalamic/suprasellar location, the thala-
mus and basal ganglia (optic tract), the brainstem, the 
cerebellar peduncle, and in tumors of the occipital or 
temporomesial lobe. Deficits in visual acuity were distrib-
uted into mild (0.9–0.5) and severe (0.4–0), visual field 
deficits into partial anopsia and complete hemianopsia 
Figure 4. Selected treatment example indicating a child exhibiting a WHO grade I astrocytoma of the hypothalamic area undergoing combined 
treatment (A) before treatment, (B) after best safe resection, (C) Iodine- 125 stereotactic brachytherapy (SBT) irradiation planning (two seeds), (D) 
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and oculomotor function into mild (incomplete affection 
of one oculomotor nerve) and severe (complete affection 
of one or more oculomotor nerves) deficits. Functional 
outcome was classified as improved (increased visual acuity 
of ≥0.2, decreased mean defect according to visual field 
perimetry, complete remission of mild or improvement 
of severe oculomotor deficits), deteriorated (decreased 
visual acuity of ≥0.2, increased mean defect, worsening 
of oculomotor function from mild to severe or corre-
sponding new deficits); otherwise visual function was 
classified as unchanged. In hypothalamic/suprasellar tumor 
location endocrinological evaluation included basal serum 
levels of growth hormone GH, Insulin- like- growth factor 
IGF- 1, ACTH, baseline cortisol, prolactin, luteinizing and 
follicle stimulating hormone LH and FSH, thyreotropine 
TSH and thyroid hormone, testosterone, and estradiol. 
Neurohypophyseal function was determined by serum 
sodium and osmolarity level, fluid intake and output and 
urine specific gravity level. Endocrinological deficits were 
pre and postoperatively categorized as anterior or posterior 
hypopituitarism. This classification concerned both those 
with complete and incomplete insufficiency of the affected 
lobe. In case of involvement of both lobes (partial or 
complete), insufficiency was classified as panhypopituita-
rism. Postoperative improvement was assumed in case of 
both complete recovery of at least one affected hormonal 
axis and at least unchanged findings in the remaining 
axes. Any new complete or partial insufficiency of a single 
hormonal axis 6 weeks after surgery was classified as 
deterioration. Otherwise the endocrinological status was 
classified as unchanged.
Disappearance of seizures (with/without anticonvulsive 
drugs) was classified as improvement. An increased seizure 
activity (including frequency and/or semiology) or a new 
onset of seizures at the time of last follow- up was clas-
sified as deterioration. Otherwise a stabilized unchanged 
seizure status was assumed.
Statistical analysis
The reference point of the study was the date of seed 
implantation. Date of last follow- up was April 2015. Primary 
endpoints were tumor progression, functional outcome, 
and treatment toxicity. Continuously scaled variables were 
described as median (mean) including the range of their 
distribution. Patient- and tumor- related variables were 
analyzed and compared with the chi- squared statistics (for 
dichotomized variables) and the Wilcoxon test (for con-
tinuously scaled variables); Wilcoxon test for related sam-
ples was used to analyze changes of functional variables 
over time. Time to tumor progression and time to malig-
nant transformation were analyzed with the Kaplan–Meier 
method. Survival curves were compared with the log- rank 
test. Prognostic factors were obtained from proportional 
hazards models. A P- value ≤0.05 was considered significant. 
All calculations were performed using the SAS software 
package version 9.2 Heidelberg, Germany.
Results
The study population comprised 58 patients (23 female, 
35 male) with a median age of 9 years (median follow-
 up: 49 months [12–162]). Thirteen patients were younger 
than 5 years. Five patients had progressive tumors after 
pervious chemotherapy. Those with recurrent tumors are 
not different form the others in terms of histology, age, 
Lansky score, and tumor size. WHO grade I tumors were 
found in 43 patients. Seven patients were suffered from 
neurofibromatosis type I (NF- 1). Patients with grade II 
tumors had better initial Lansky scores (P = 0.04) and 
more often lobar located tumors (P = 0.004). Shunt place-
ment before tumor treatment was done in six patients. 
Patients′ characteristics are summarized in Table 1. MGMT 
promoter methylation (2/24 tumors), mutated IDH 1/2 
status (1/23), or LOH 1p/19q codeletion (2/23) were sel-
dom found, whereas a BRAFV600E mutation/presence of 
BRAF-KIAA1549 fusion transcripts were frequently seen 
in WHO grade I tumors (10/16).
Thirty- nine patients underwent SBT alone and 19 
patients a combined treatment. The initial tumor volume 
was 26 ccm in the combined group and 5.1 ccm in the 
SBT only group (P = 0.001); this difference was no longer 
present after best tumor resection (4.8 ccm vs. 5.1 ccm). 
Tumors of the hypothalamic region were more often seen 
in the combined group (P = 0.03), whereas tumors of 
the thalamus/basal ganglia and the brainstem predomi-
nantly occurred in the SBT only group (P = 0.001). The 
SBT only and the combined group did not differ in terms 
of age, Lansky score, tumor type and the frequency of 
preoperative functional deficits (Table 1). Seeds have been 
removed after a median time interval of 550 h [220–1200] 
after implantation in an outpatient manner; no complica-
tions have been observed.
Treatment response
Best treatment response was seen after a median time of 
16 months after SBT; complete response (CR), partial 
response (PR), and stable disease (SD) occurred in 10, 
28, and 20 patients, respectively (Fig. 2–4 display treat-
ment examples). Seven patients (12%) exhibited biopsy 
proven progressive disease (PD) including one patient 
with malignant transformation of a previous WHO grade 
II astrocytoma. Response rates were identical in both 
treatment groups and not influenced by the NF- 1 status. 
Two patients had died due to tumor progression. One 
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of these children suffered from a malignant transforma-
tion of an initial astrocytoma WHO grade II 24 months 
after initial treatment. Overall, 5- year progression- free 
survival (PFS) and 5- year overall survival (OS) were 87% 
(95% CI: 69.8–94.5) and 95% (95% CI: 81.9–98.8), respec-
tively. Favorable factors for PFS were CR/PR (P = 0.005) 
and a Lansky score ≥90 (P = 0.02); tumors with a BRAFV600E 
mutation/BRAF-KIAA1549 fusion transcripts (10/16) 
showed more often CR/PR (8/10 vs. 1/6; P = 0.04). WHO 
grade (P = 0.7), tumor location (P = 0.5), tumor size 
(P = 0.2), NF- 1 status (P = 0.6) and the applied tailored 
treatment strategy (P = 0.8) did not gain prognostic influ-
ence. Progression- free survival (PFS) is detailed in Figure 5. 
Two children, harboring grade I gliomas, experienced late 
tumor progression 95 and 108 months after initial treat-
ment. One patient has received combined treatment and 
the other one SBT alone. BRAFV600E mutation was seen 
in one patient. Progression was proven by biopsy in one 
patient, who underwent subsequent Re- SBT. The other 
underwent open tumor resection. Histological reevaluation 
revealed a grade I tumor recurrence. Salvage treatment 
after progression consisted of resection alone (n = 3), 
resection plus external beam irradiation (n = 1), SBT 
retreatment (n = 1), chemotherapy (n = 1), or combined 
radiochemotherapy (n = 1). The 5- year estimated risk to 
receive additional radiotherapy/chemotherapy was 5.2%.
Functional outcome
At the time of last follow- up, the median Lansky score 
of the survivors (n = 56) was 90 [60–100]; the differences 
between the respective performance scores preoperatively 
and at last follow- up were statistically not significant 
(P = 0.7). Functional outcome was not influenced by the 
mode of treatment. Deficits were initially seen in 41 patients 
and occurred significantly more often in case of a hypo-
thalamic tumor location (P = 0.003). Those children 
without functional deficits preoperatively (n = 17) remained 
all asymptomatic at the time of last follow- up. In surviv-
ing patients initially exhibiting functional deficits (n = 39) 
improvement, stabilization, and deterioration were seen 
in 20, 14, and 5, respectively. Functional improvement 
occurred more often after CR or PR compared to those 
with SD (P = 0.02). Functional deterioration was more 
often observed in those suffering from PD; the difference, 
however, was statistically not significant. In detail, improve-
ment concerned 9/13 motor- , 11/19 visual- (visual acuity, 
perimetry, and oculomotor function), 3/14 endocrine- , 
and 6/6 seizure- associated deficits; deterioration concerned 
1/13 motor- and 2/14 endocrine- associated deficits; new 
functional postoperative deficits included oculomotor dis-
turbance and endocrine deficits in respective one patient 
(Table 2). Improvement concerned more often motor/
Table 1. Patients’ characteristics (n = 58).
Characteristics
Therapy n (%) Treatment parameters of SBT Median[range] P Value
Microsurgery + SBT 19 (32.8%) 54 Gy, 11.3 cGy/h [10–18], 450h* *n.s.
SBT 39 (67.2%) 54 Gy, 9.4 cGy/h [4–15], 600h*
Overall Microsurgery + SBT SBT P Value
Age (years) Median [range] 9 [0.9–17] 8 [1.5–16] 11 [0.9–17] n.s.
Sex
Female 23 (40%) 3 (16%) 20 (51%) 0.02
Male 35 (60%) 16 (84%) 19 (49%)
Lansky score Median [range] 90 [60–100] 90 [60–100] 90 [60–100] n.s.
Histology
WHO I 43 (74%) 16 (84%) 27 (69%) n.s
WHO II 15 (26%) 3 (16%) 12 (31%)
Location
Lobar 11 (19%) 5 (26%) 6 (15.5%) n.s.
Hypothalamic/suprasellar 16 (28%) 9 (47%) 7 (18%) 0.03
Thalamus/basal ganglia 15 (26%) 0a 15 (38.5%)c (a)+(b) versus (c)+(d)
Brainstem 9 (15%) 2 (11%)b 7 (18%)d 0.001
Cerebellum (pedunculus) 7 (12%) 3 (16%) 4 (10%) n.s.
Tumor volume (ccm) Median [range] (e) versus (f)  
(e) versus (g)
Before microsurgery 8.7 [0.4–88] 26 [3.5–88]a – 0.001
Before SBT 4.8 [0.4–21] 4.8 [0.4–19]b 5.1 [0.7–21]c (f) versus (g) n.s.
WHO, World Health Organization; SBT, Iodine- 125 stereotactic brachytherapy; Gy, Gray; h, hours; n.s., not significant.
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Figure 5. Kaplan–Meier curves of progression- free survival (PFS) stratified by (A) treatment modality (stereotactic low- dose rate Iodine- 125 
brachytherapy (SBT) only versus combined with best safe microsurgical resection), (B) WHO grade I versus II and (C) overall best treatment response 




Table 2. Functional outcome.
Preoperative deficits N (%) Postoperative outcome at last F/U
Improvement Stabilization Deterioration New deficit
Motor
Mild 7 5 2 0 0
Severe 6 4 1 1 0
Total 13 (22) 9 (69.2) 3 (23.1) 1 (7.7) 0
Visual
Visual acuity
Mild 6 3 3 0 0
Severe 4 2 2 0 0
Visual field disturbances
Partial deficit 4 3 1 0 0
Hemianopsia 3 2 1 0 0
Oculomotor disturbances
Mild 1 1 0 0 0
Severe 1 0 1 0 1
Total 19 (33) 11 (57.9) 8 (42.1) 0 1 (1.8)
Endocrinological function
Anterior hypopituitarism 7 1 5 1 1
Posterior hypopituitarism 3 1 2 0 0
Pan- hypopituitarism 4 1 2 1 0
Total 14 (24) 3 (21.4) 9 (64.3) 2 (14.3) 1 (1.8)
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visual/seizure- associated deficits whereas endocrine func-
tion often remained unchanged or even worsened 
(P = 0.04).
Treatment toxicity
The overall early toxicity rate was 8.6%. Early grade 1 
and 2 toxicities have been observed in 1 and 3 patients, 
respectively (transient deterioration of a preexisting hemi-
paresis). Early grade 3 toxicity was seen in one patient 
(progressive hydrocephalus demanding shunt surgery).
The overall late toxicity rate was 10.3% (grade 2: 3 
patients, grade 3: 3 patients; Fig. 6). Most events (83%) 
were seen within the first 2 years after SBT. The estimated 
1- and 2–year risk of late treatment toxicity was 6.4% 
and 10.3%, respectively. Patients suffering from late treat-
ment toxicity had significantly larger tumor volumes 
(11.1 ccm vs. 4.5 ccm; P = 0.02). Complications were 
manageable in all patients and did not result in permanent 
morbidity: three patients were transiently treated with 
steroids (median treatment time: 21 days); in two patients 
surgical treatment with necrosectomy became necessary; 
additionally, one patient suffered from an intralesional 
bleeding of a blister aneurysm of the internal carotid 
artery 7 years after implantation requiring surgical occlu-
sion. Ad hoc analysis of the dose distribution indicated 
that the high- dose zone (200 Gy isodose) had included 
parts of the internal carotid artery.
Symptomatic pseudocyst formation after 
SBT
Symptomatic space- occupying pseudocyst formations were 
seen in 11 patients (19%). The estimated 1- and 2–year 
risk for symptomatic pseudocysts was 9 and 23%, respec-
tively. Clinical symptoms completely resolved after 
stereotactically guided drainage in all cases (internal shunt 
(6)/stereotactic aspiration (5)); no risk factor could be 
identified.
Discussion
The role of SBT for initial treatment of PLGGs is still 
under debate. In a recently published multicenter treat-
ment study for PLGGs (HIT- LGG–1996), for example, 
SBT has been classified as a mode of radiation therapy 
and was therefore used in a delayed fashion for selected 
small- sized progressive tumors [6]. Stereotactic Iodine- 125 
brachytherapy (SBT), however, integrates biological char-
acteristics of both radiosurgery and fractionated external 
beam radiation: The application of a highly localized 
intratumoral necrotizing dose in the vicinity of the radio-
active source (high- dose zone) goes hand in hand with 
protective effects of fractionation particularly in the micro-
environment of the interface between normal brain and 
neoplastic cells [21, 22, 31]. Given the highly localized 
treatment effects of SBT, it is tempting to use SBT – in 
analogy to surgical treatment – as primary treatment 
modality for complex located PLGGs. This approach was 
tested in our previously published pilot study[13] and is 
now further explored in the current report. Given the 
fact that tumor volume restrictions exist for SBT [20, 
22], a tailored surgical treatment concept was tested: 
Small- sized complex located PLGGs were treated by SBT 
alone, whereas larger tumors underwent best safe resection 
and SBT of the residual tumor thereafter. It was hypoth-
esized that the early use of SBT alone or in combination 
with best safe resection offers the possibility to treat the 
entire tumor volume in complex located PLGGs. It is 
important to note that SBT was used as upfront treat-
ment strategy in order to avoid/withhold adjuvant treat-
ment such as chemotherapy/conventional radiotherapy, or 
Figure 6. Kaplan–Meier curve indicating late treatment toxicity after Iodine- 125 stereotactic brachytherapy (SBT) with respective detailed toxicities 
shown.
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new molecular based therapies currently under investiga-
tion. The somewhat unique radiobiological characteristics 
of SBT explain that long- term radiogenic complications 
are generally not expected to occur and that the treat-
ment spectrum is not narrowed by early SBT. In other 
words, fractionated radiotherapy still remains a valuable 
and safe treatment option for progressive tumors after 
previously performed SBT [20, 22, 23, 32].
This is to our knowledge the first study, which sys-
tematically analyzed SBT alone or in combination with 
microsurgery (in case of larger tumors) as an early treat-
ment concept for pediatric patients with unresectable, 
complex located gliomas under consideration of a detailed 
functional outcome analysis. We here demonstrate that 
both SBT alone and combined treatment of PLGGs is 
associated with PFS rates as long as that reported after 
complete resection in more recent studies (5–year PFS: 
87% in the current series vs. approximately 90%) [6–8, 
33]. Furthermore, SBT alone as compared to microsurgery 
(in combination with SBT) for larger tumors has been 
shown to be similar effective. Prognostic evaluation revealed 
favorable influence of a Lansky score ≥90. The presence 
of BRAFV600E mutation/BRAF-KIAA1549 fusion was more 
often associated with CR/PR. The impact of this biomarker 
on PFS has been recently reported [12, 34, 35].
The results of the current report could not be easily 
compared with that of other studies dealing with SBT in 
PLGGs. These studies had relied in parts on CT- data 
alone for treatment planning and response evaluation, 
performed SBT inconsistently sometimes early or delayed, 
and did not systematically analyze combined concepts for 
larger tumors [23, 32].
Whether the early use of SBT alone or in combina-
tion with best safe resection might attract a higher 
efficacy than delayed SBT remains unknown and deserves 
further prospective evaluation. The impact of initial 
treatment, however, should not be underestimated: Initial 
complete resection has turned out to be one of the 
strongest favorable prognostic factors (for PFS and OS) 
in the HIT- LGG- 1996 study supporting a concept of 
early radical surgical treatment; unfortunately, complete 
resection was only possible in 359 out of 1031 patients 
mostly due to highly eloquent tumor locations [6]. We 
here show that the applied tailored treatment concept 
enables treatment of the entire tumor volume (as depicted 
on the MRI) in complex located unresectable or only 
partial resectable PLLGs. The chosen approach overcomes 
limitations typically associated with SBT (i.e., tumor 
size) or microsurgical treatment (i.e., eloquent tumor 
location); patients harboring larger tumors or deep seated 
ones did not do worse in terms of PFS in the current 
series which contrasts finding of recently published 
reports [6, 23].
Studies on functional deficits after treatment are 
extremely scarce. We here show that the applied tailored 
treatment strategy could either improve or stabilize func-
tional deficits in the overwhelming number of patients 
(87%). Functional recovery/stabilization rates were not 
different in both treatment groups. We found associations 
between treatment response and functional outcome: those 
undergoing complete/partial response did significantly bet-
ter than those exhibiting tumor control. Seventeen patients 
were asymptomatic at the time of treatment and considered 
to be at risk of functional deterioration due to their com-
plex tumor location. All these patients continued to be 
asymptomatic at the time of last follow- up supporting 
our concept of early treatment. The preservation/improve-
ment of function in the majority of patients was in line 
with the hypothesized protective effects of both SBT and 
best safe resection. The provided data might be regarded 
as a basis against which other functional outcome data 
of future studies could be compared. However, long- term 
analysis is necessary to confirm these study results.
We further show that chemotherapy and/or external 
beam radiation could be withheld in the vast majority 
of patients including 13 patients younger than 5 years of 
age; this subpopulation has been shown to be in particular 
vulnerable to the effects of external beam radiation [9]. 
The estimated risk for receiving adjuvant treatment was 
nearly identical with that reported after complete resec-
tion; it strongly contrasts risk profiles for adjuvant treat-
ment after partial resection or biopsy only (estimated 
5–year risk for adjuvant treatment after subtotal resection: 
approximately 45%; after partial resection/biopsy only: 
approximately 75%) [6].
Ideally, expected long- term survival should go hand in 
hand with diminishing of long- term treatment- related 
complications. We observed a blister aneurysmal bleeding 
of the internal carotid artery 7 years after treatment in 
one patient. Re- analysis of the radiation plan indicated 
high- dose radiation in the area of the occurring aneurysm. 
Even though other studies have reported on occlusive 
arteriopathies after high- dose radiation [36], the risk of 
a radiation- induced aneurysm has not been acknowledged 
so far. Given the extreme heterogeneity of the radiation 
field of SBT and the strong interrelation between both 
vessels and the tumor particularly in case of suprasellar 
tumors or those of the insula of Reil, high- dose radiation 
of arteries is sometimes difficult to avoid. Unfortunately, 
analyses concerning threshold doses and the risk of SBT- 
induced arteriopathies are still lacking. Given the results 
of this and other reports [36], however, one should be 
aware of such risks and try to avoid high- dose radiation 
of arteries (>120 Gy) whenever possible.
The frequency of radiogenic complications occurring 
within the first 2 years after SBT was completely in line 
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with other long- term analyses dealing with SBT [20, 22]. 
The current report further confirmed the tumor volume 
before SBT to be a relevant risk factor for complications. 
The median tumor volume of those exhibiting a radiogenic 
complication was 11.1 ccm. Given these results indications 
of SBT for larger tumor volumes should be critically 
evaluated concerning their potential benefit and their risk. 
The sample of this study, however, was not suitable to 
define a threshold volume beyond that radiogenic com-
plications might occur.
Low- grade gliomas can develop pseudocyst formations 
during the course of the disease. The impact of treatment 
on this phenomenon remains unclear. The observed fre-
quency in the current report appeared to be in line with 
other reports [23, 32]. Pseudocyst formations can be usu-
ally managed by stereotactic guided aspiration or implan-
tation of an “internal” shunt catheter thereby immediately 
relieving clinical symptoms.
In summary, we provide evidence that tailored surgical 
treatment using either SBT alone or in combination with 
best safe resection extends the initial treatment platform 
for unresectable or incompletely resectable PLGGs: favorable 
risk profile, preservation of function, and PFS as long as 
after complete resection might be regarded as the hallmarks 
of this new treatment concept for complex located PLGGs.
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